Table 3 Adverse events attributed (possibly, probably, or definitely) to DFMO.
From: Maintenance DFMO Increases Survival in High Risk Neuroblastoma
n = 140 | Grade 2 | Grade 3 | Grade 4 | Grade 5 |
|---|---|---|---|---|
Hematologic Toxic Effects | ||||
Anemia | 4 (3%) | 2 (1%) | ~ | ~ |
Neutrophil count decrease | 7 (5%) | 4 (4%) | ~ | ~ |
Platelet count decrease | 2 (1%) | ~ | ~ | ~ |
White blood cell decreased | 3 (2%) | ~ | ~ | ~ |
Non-hematologic Toxic Effects | ||||
Abdominal Pain | 1 (<1%) | ~ | ~ | ~ |
Agitation | 1 (<1%) | ~ | ~ | ~ |
Alopecia | 2 (1%) | ~ | ~ | ~ |
ALT elevation | 7 (5%) | 5 (4%) | ~ | ~ |
AST elevation | 5 (4%) | 4 (4%) | ~ | ~ |
Alkaline phosphatase elevation | 1 (<1%) | ~ | ~ | ~ |
Anorexia | 1 (<1%) | ~ | ~ | ~ |
Diarrhea | 6 (4%) | 1 (<1%) | ~ | ~ |
Fever | 4 (3%) | ~ | ~ | ~ |
Hearing Loss | 1 (<1%) | 5 (4%) | ~ | ~ |
Hypoglycemia | ~ | ~ | 1 (<1%) | ~ |
Hypokalemia | ~ | 2 (1%) | ~ | ~ |
Infection, Other | 3 (2%) | ~ | ~ | ~ |
Infection, middle ear | 6 (4%) | ~ | ~ | ~ |
INR Elevated | 1 (<1%) | ~ | ~ | ~ |
Insomnia | 1 (<1%) | ~ | ~ | ~ |
Pain | 2 (1%) | ~ | ~ | ~ |
Post Nasal Drip | 1 (<1%) | ~ | ~ | ~ |
Rash | 3 (2%) | ~ | ~ | ~ |
Vomiting | ~ | 1 (<1%) | ~ | ~ |
Weight Gain | 1 (<1%) | ~ | ~ | ~ |
